" class="no-js "lang="en-US"> CNS Pharmaceuticals Archives - Medtech Alert
Wednesday, March 22, 2023

Breaking News

Axel Hoos, MD, PhD, Joins NextPoint Therapeutics Board of Directors Coya Therapeutics Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS) BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey Mindset Health Raises $12M to Expand Digital Hypnotherapy Apps & Scale Distribution GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey” Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis Gamida Cell Announces Changes to Board of Directors Newron Reports Topline Results From All Patients in Study Evaluating Evenamide as Add-on Therapy for Treatment-Resistant Schizophrenia Ascidian Therapeutics Appoints Jay A. Barth, M.D., as Chief Medical Officer TFS HealthScience Expands Operations into Israel, With Focus on Continuous, Rapid International Expansion

Sort by:

Date

Top Post

FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's Disease | MTA

FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's Disease

Eisai and Biogen announced today that the US Food and Drug Administration (FDA) has accepted […]

Read more

News

 CNS Pharmaceuticals Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM with First Patient Enrolled in Switzerland | MTA

CNS Pharmaceuticals Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM with First Patient Enrolled in Switzerland

CNS Pharmaceuticals, a biopharmaceutical company specializing in the development of novel treatments for primary and […]

Clinical Trials

 CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM | MTA

CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

CNS Pharmaceuticals, a biopharmaceutical company specializing in the development of novel treatments for primary and […]

Clinical Trials

 CNS Pharmaceuticals Announces Investigator-Initiated Phase 1b/2 Trial | PTF

CNS Pharmaceuticals Announces Investigator-Initiated Phase 1b/2 Trial to be Conducted at the Pomeranian Medical University in Poland

CNS Pharmaceuticals, a biopharmaceutical company specializing in the development of novel treatments for primary and […]

Appointments

 CNS Pharmaceuticals Appoints Faith L. Charles, JD as Chair of the Board of Directors | PTF

CNS Pharmaceuticals Appoints Faith L. Charles, JD as Chair of the Board of Directors

CNS Pharmaceuticals, a biopharmaceutical company specializing in the development of novel treatments for primary and […]

  1. Axel Hoos, MD, PhD, Joins NextPoint Therapeutics Board of Directors

    Appointments

     Read more
  2. Coya Therapeutics Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS)

    Clinical Trials

     Read more
  3. BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey

    News

     Read more
  4. Mindset Health Raises $12M to Expand Digital Hypnotherapy Apps & Scale Distribution

    Fundraising

     Read more
  5. GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey”

    Diseases

     Read more